The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family.
 
Howard A. Burris
No Relationships to Disclose
 
Marcia S. Brose
Honoraria - Bayer; Exelixis; Onyx
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Exelixis; Onyx; Oxigene
Research Funding - Bayer (Inst); Eisai (Inst); Exelixis (Inst); Novartis (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Onyx
 
Alice Tsang Shaw
No Relationships to Disclose
 
Todd Michael Bauer
No Relationships to Disclose
 
Anna F. Farago
No Relationships to Disclose
 
Robert Charles Doebele
No Relationships to Disclose
 
Steven Smith
Consulting or Advisory Role - Loxo
 
Michele Fernandes
Employment - Loxo
 
Scott Cruickshank
Consulting or Advisory Role - Loxo
 
Jennifer A. Low
Employment - Genentech/Roche; Loxo
Leadership - Loxo
Stock and Other Ownership Interests - Loxo; Roche/Genentech